Another investigational drug of the company under FDA review is Donidalorsen, proposed for the treatment of hereditary angioedema, a rare genetic disorder that causes severe swelling episodes.

Suggested remit: To appraise the clinical and cost effectiveness of Donidalorsen within its marketing authorisation for treating angioedema.

Donidalorsen is an investigational RNA-targeted medicine designed to reduce the production of prekallikrein (PKK), a protein that plays an important role in the activation of inflammatory ...

Theratechnologies gains exclusive rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals, olezarsen and donidalorsen ・Submissions to Health Canada are planned for 2025 ...